# FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13s – 16 or 15d – 16 of the Securities Exchange Act of 1934

For the month of December 2004

# **Acambis plc**

(Translation of registrant's name into English)

Peterhouse Technology Park 100 Fulbourn Road Cambridge CB1 9PT England

(address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F).

Forms 20-F Form 40-F

(Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934).

Yes No

(If []Yes[] is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ).

#### **Enclosure:**

Schedule 10 notification of major interests in shares: 26 November 2004

Increase in Directors' shareholdings: 8 December 2004

#### **SCHEDULE 10**

#### **NOTIFICATION OF MAJOR INTERESTS IN SHARES**

1. Name of company

#### Acambis plc

2. Name of shareholder having a major interest

INVESCO Perpetual UK Investment Series Limited ("UK ICVC")

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

#### As above

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

#### Vidacos Nominees Limited

5. Number of shares / amount of stock acquired

#### 344,087 shares

6. Percentage of issued class

#### 0.32%

7. Number of shares / amount of stock disposed

#### N/a

8. Percentage of issued class

#### N/a

9. Class of security

#### Ordinary shares of 10p each

10. Date of transaction

#### 24 November 2004

11. Date company informed

#### 25 November 2004

12. Total holding following this notification

#### 18,385,000 shares

13. Total percentage holding of issued class following this notification

#### 17.16%

14. Any additional information

#### Notification provided by AMVESCAP as an agent for UK ICVC

Holding for SAR purposes is 25,752,461 shares representing a 24.04% holding

15. Name of contact and telephone number for queries

#### Elizabeth Brown, Company Secretary

+44 (0) 1223 275 300

16. Name and signature of authorised company official responsible for making this notification

#### Elizabeth Brown

Date of notification

## 26 November 2004

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

### Increase in Directors' shareholdings

**Cambridge, UK** [] **8 December 2004** [] Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM)ounces a transaction involving a Directors shareholding in Acambis.

On 6 November 2004, Nicolas Higgins, Chief Business Officer, exercised 6,250 options at 152p per share over 10p ordinary shares granted under the Acambis 1995 Savings-Related Share Option Scheme. Following this transaction, Mr Higgins' shareholding in Acambis has increased from 137,946 to 144,196 shares, representing approximately 0.13% of Acambis' issued ordinary share capital. Of these 144,196 shares, 30,068 are held by the Trustees of Acambis Employees' Trust on behalf of Mr Higgins.

-ends-

## **Enquiries:**

#### **Acambis plc**

Lyndsay Wright, Director of Communications Tel: +44 (0) 1223 275 300

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant Peptide Therapeutics Group has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 23 December, 2004 ACAMBIS PLC

By: /s/ Lyndsay Wright

Name: Lyndsay Wright

Title: Director of Communications